Read This First
This page is not built on clinical evidence. Cost and access are commercial and legal facts, not scientific findings. They come from the regulatory record in Russia, where semax is a medicine, and in the United States, where it is not, and they change on timescales of months.
Semax has a price in Russia, where it is sold as nasal drops on the ordinary terms of a registered pharmaceutical. It has no price, no prescription route and no insurance pathway anywhere else, because no other regulator has approved it and the FDA's advisory committee recommendation of July 2026 has not been acted on.1
This page publishes no prices. What follows is what determines the money, which for this compound begins with a border.
Why There Is No Single Price
Two Markets That Do Not Touch
In Russia, semax is priced like an over-the-counter or prescription nasal drop, made by a licensed manufacturer to a national standard for specified indications. Outside Russia, three different things are sold under its name: the Russian product exported beyond its lawful market, US-compounded or vendor-made nasal sprays, and injectable powder for a route no human study has ever used.1 Each has a different price, and none of the three outside Russia is a verified product.
What a Price Normally Represents
For an approved medicine, a price sits on top of a known quantity of a known substance, made to a validated standard, for a stated indication, with a documented effect. In Russia, semax has all of those, for stroke and a few neurological uses, on the basis of trials a non-Russian reader cannot examine. Outside Russia it has none of them, and the effect it is sold for, cognitive enhancement in healthy people, is one the Russian registration does not cover either.
Access
Is There a Legal Route in the United States?
No. Semax is not approved, is not a component of an approved drug, and is not on the 503A bulks list. It was placed in the FDA's Category 2 of nominated compounding substances in September 2023 and is now listed as nominated but withdrawn.2 There is no clinical trial to join; none is registered.
What Did the July 2026 Vote Do?
On 24 July 2026 the FDA's advisory committee voted 8 to 5, with one abstention, to recommend semax for the bulks list for cerebral ischaemia, migraine and trigeminal neuralgia, over the FDA's objection on every criterion.31 The recommendation is advisory, the list can only be amended by rulemaking, and the FDA has not begun one. If it eventually acts, semax would become compoundable on prescription for those three neurological conditions. Cognitive enhancement, anxiety, ADHD and the rest of the marketed list were not before the committee and would not be covered.
Can the Russian Product Be Imported?
Not lawfully as a rule. Importing an unapproved drug for personal use is prohibited; the FDA's enforcement discretion is limited to serious conditions with no US treatment, a small supply and a US physician's involvement, and a nootropic nasal spray does not meet that. ONPEPS does not advise on customs law. What it can say is that the one semax injury in the FDA's adverse event database involved drops bought online from a retailer, and that a buyer of imported product is trusting the retailer for genuineness, storage and formulation.1
Does Insurance Cover It?
Not outside Russia, and there is nothing to appeal. Payers reimburse approved products for approved indications. A compounded product on a bulks list, if it ever exists, would still not be an approved drug.
Can HSA or FSA Funds Be Used?
Tax-advantaged health accounts cover qualified medical expenses, which generally requires a legitimate medical purpose and often a provider's documentation. A product that cannot lawfully be dispensed in the United States sits poorly against that. The account holder carries the consequences of a disallowed expense; the question belongs with the plan administrator.
What the Money Buys
Where Does the Spread Between Channels Come From?
| Channel | What is supplied | What the price includes | What it does not |
|---|---|---|---|
| Russian pharmacy, in Russia | Registered nasal drops | A product a regulator has reviewed, for its registered uses | Any use beyond those; availability outside Russia |
| Online retailer, imported drops | The Russian product, or something labelled as it | A box and a label | Verification of genuineness; lawful import; any recourse |
| US clinic or vendor, nasal spray | Semax powder in a spray device | A consultation, sometimes; a bottle | Any information on whether the device delivers a dose, which the FDA found absent1 |
| Vendor, injectable powder | Semax for subcutaneous injection | A vial | Any human data by that route; sterility assurance |
ONPEPS publishes no prices; read this as reasoning about cost structure rather than a measured breakdown. What the spread never buys outside Russia is the thing the compound's reputation rests on: a nasal product made to the standard the Russian trials used, delivering the dose they delivered, by the route that reaches the brain.
What Does the Stack Add?
Semax is commonly sold with selank, a peptide from the same Moscow institute, as a paired "focus and calm" protocol.1 No study has tested the combination. A stack price cannot be attributed to either component, which is the commercial point of a stack, and it is not more evidence-based than its weaker member.
The Spending Decision
What Result Is Being Paid For?
Outside Russia, mostly cognition: focus, memory, attention. The evidence for that in humans is a 1996 study of attention in 19 healthy men and two imaging studies in 14 volunteers showing a change in a resting-state brain network after a single dose.4 The stroke trials, whatever they show, concern people recovering from a stroke, and the FDA could not read them.1 The rat work on BDNF is real and does not transfer.5
A buyer of semax for focus is paying for a Russian stroke drug's brand, delivered by a device nobody has qualified, for an outcome no controlled trial has measured.
Semax has a better preclinical story than most of this library and a registration from a real regulator. Both belong to a nasal drop for neurological disease in Russia. Neither belongs to a vial in a US mailbox.
What Is the Risk Side of the Ledger?
Probably low for the Russian product used as registered, and less clear for everything else. The FDA identified two specific items: a possible anti-thrombotic property that "raises concern about the risk of bleeding" in at-risk people or alongside blood-thinning medication, and a 2025 report of eye pain and burning after online-bought drops that led to hospitalisation and symptoms lasting a year.1 For the injectable route there is no safety data at all.
What Should Be Asked Before Paying?
Is this the Russian registered product, a compounded spray, or powder? The answer determines everything else.
For a spray, what device is it in, and what evidence is there that the device delivers a consistent dose?
Which human study, by this route, measured the outcome you are promising for someone without a stroke?
Are you aware the FDA raised a bleeding concern, and do you ask whether buyers take anticoagulants?1
Are you aware the July 2026 recommendation has not been adopted, and on what legal basis are you supplying this?
Does anyone here earn commission on product sales?
What Would Change This Page
The FDA's Decision, or a Readable Trial
The FDA's action on the July 2026 recommendation would change the access position for three neurological conditions. An English-language, blinded trial by any route would change the evidence position for the first time. Neither is scheduled. The ONPEPS July 2026 article covers the possible routes and their timescales.
A Note on "It's a Prescription Drug in Russia"
True, and the most common thing said in its favour. The Russian registration covers nasal drops for stroke and a few neurological conditions, on the basis of trials that have not been independently reviewed. It does not cover cognitive enhancement, it does not cover injection, and it is not a price signal for anything sold outside Russia. ONPEPS treats it as a fact about one regulator, not as evidence.
Related ONPEPS Coverage
Semax library entry: the Russian registration, the excluded trials and the July 2026 vote
Semax sourcing and quality: a Russian drug, a nasal spray and a vial
Sources
US Food and Drug Administration. Semax-related bulk drug substances (semax (free base) and semax acetate): FDA presentation to the Pharmacy Compounding Advisory Committee, 24 July 2026. Docket FDA-2025-N-6895. fda.gov
US Food and Drug Administration. Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Entry for semax (heptapeptide). Content current as of 22 April 2026. fda.gov
ONPEPS. FDA peptide news July 2026: the only source you need. Records the 8 to 5 vote with one abstention on semax. onpeps.com
Lebedeva IS, Panikratova YR, Sokolov OY, Kupriyanov DA, Rumshiskaya AD, Kost NV, et al. Effects of Semax on the default mode network of the brain. Bull Exp Biol Med. 2018;165(5):653-656. Paywalled. pubmed.ncbi.nlm.nih.gov/30225715
Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. Paywalled. pubmed.ncbi.nlm.nih.gov/16996037
Not Medical or Financial Advice
Semax is a registered medicine in Russia and an unapproved substance everywhere else. Treatment decisions belong with a qualified healthcare provider. Nothing on this page is a recommendation to buy or not to buy anything; it is an account of what determines what the money would be spent on.
Sources verified 16 September 2026. The FDA's action on the July 2026 recommendation would change the access section of this page. Re-verify before relying on anything here.